{"generic":"Aztreonam","drugs":["Azactam","Aztreonam","Cayston"],"mono":{"0":{"id":"53342-s-0","title":"Generic Names","mono":"Aztreonam"},"1":{"id":"53342-s-1","title":"Dosing and Indications","sub":[{"id":"53342-s-1-4","title":"Adult Dosing","mono":"<ul><li>(inhalation) safety and effectiveness have not been established in patients with FEV1 less than 25% or greater than 75% predicted, or in patients with Burkholderia cepacia<\/li><li><b>Bacterial meningitis:<\/b> 6 to 8 g\/day IV divided every 6 to 8 hours<\/li><li><b>Cystic fibrosis:<\/b> following bronchodilator use, 75 mg (1 vial, reconstituted with 1 mL sodium chloride 0.17%) INHALED via Altera Nebulizer System(R) 3 times daily (at least 4 hours apart) for 28 days<\/li><li><b>Disease due to Gram-negative bacteria:<\/b> (moderately severe systemic infections) 1 or 2 g IV\/IM every 8 or 12 hours (MAX dose, 8 g\/day)<\/li><li><b>Disease due to Gram-negative bacteria:<\/b> (severe systemic or life-threatening infections, or any infection caused by P. aeruginosa) 2 g IV every 6 or 8 hours (MAX dose, 8 g\/day)<\/li><li><b>Endometritis:<\/b> (moderately severe systemic infections) 1 or 2 g IV\/IM every 8 or 12 hours (MAX dose, 8 g\/day)<\/li><li><b>Endometritis:<\/b> (severe systemic or life-threatening infections, or any infection caused by P. aeruginosa) 2 g IV every 6 or 8 hours (MAX dose, 8 g\/day)<\/li><li><b>Female genital infection:<\/b> (moderately severe systemic infections) 1 or 2 g IV\/IM every 8 or 12 hours (MAX dose, 8 g\/day)<\/li><li><b>Female genital infection:<\/b> (severe systemic or life-threatening infections, or any infection caused by P. aeruginosa) 2 g IV every 6 or 8 hours (MAX dose, 8 g\/day)<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> (moderately severe systemic infections) 1 or 2 g IV\/IM every 8 or 12 hours (MAX dose, 8 g\/day)<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> (severe systemic or life-threatening infections, or any infection caused by P. aeruginosa) 2 g IV every 6 or 8 hours (MAX dose, 8 g\/day)<\/li><li><b>Infectious disease of abdomen:<\/b> (moderately severe systemic infections) 1 or 2 g IV\/IM every 8 or 12 hours (MAX dose, 8 g\/day)<\/li><li><b>Infectious disease of abdomen:<\/b> (severe systemic or life-threatening infections, or any infection caused by P. aeruginosa) 2 g IV every 6 or 8 hours (MAX dose, 8 g\/day)<\/li><li><b>Lower respiratory tract infection:<\/b> (moderately severe systemic infections) 1 or 2 g IV\/IM every 8 or 12 hours (MAX dose, 8 g\/day)<\/li><li><b>Lower respiratory tract infection:<\/b> (severe systemic or life-threatening infections, or any infection caused by P. aeruginosa) 2 g IV every 6 or 8 hours (MAX dose, 8 g\/day)<\/li><li><b>Peritonitis:<\/b> (moderately severe systemic infections) 1 or 2 g IV\/IM every 8 or 12 hours (MAX dose, 8 g\/day)<\/li><li><b>Peritonitis:<\/b> (severe systemic or life-threatening infections, or any infection caused by P. aeruginosa) 2 g IV every 6 or 8 hours (MAX dose, 8 g\/day)<\/li><li><b>Septicemia:<\/b> 2 g IV every 6 or 8 hours (MAX dose, 8 g\/day)<\/li><li><b>Urinary tract infectious disease:<\/b> 0.5 or 1 g IV\/IM every 8 or 12 hours (MAX dose, 8 g\/day)<\/li><\/ul>"},{"id":"53342-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>(injection) administer intravenously to pediatric patients with normal renal function; intramuscular administration is not recommended<\/li><li>(inhalation) safety and effectiveness have not been established in patients younger than 7 years of age, patients with FEV1 less than 25% or greater than 75% predicted, or in patients with Burkholderia cepacia<\/li><li><b>Cystic fibrosis:<\/b> age 7 years and older, following bronchodilator use, 75 mg (1 vial, reconstituted with 1 mL sodium chloride 0.17%) INHALED via Altera Nebulizer System(R) 3 times daily (at least 4 hours apart) for 28 days<\/li><li><b>Disease due to Gram-negative bacteria:<\/b> (mild to moderate infections) age 9 months and older, 30 mg\/kg IV every 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Disease due to Gram-negative bacteria:<\/b> (moderate to severe infections) age 9 months and older, 30 mg\/kg IV every 6 or 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Endometritis:<\/b> (mild to moderate infections) age 9 months and older, 30 mg\/kg IV every 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Endometritis:<\/b> (moderate to severe infections) age 9 months and older, 30 mg\/kg IV every 6 or 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Female genital infection:<\/b> (mild to moderate infections) age 9 months and older, 30 mg\/kg IV every 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Female genital infection:<\/b> (moderate to severe infections) age 9 months and older, 30 mg\/kg IV every 6 or 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> (mild to moderate infections) age 9 months and older, 30 mg\/kg IV every 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> (moderate to severe infections) age 9 months and older, 30 mg\/kg IV every 6 or 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Infectious disease of abdomen:<\/b> (mild to moderate infections) age 9 months and older, 30 mg\/kg IV every 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Infectious disease of abdomen:<\/b> (moderate to severe infections) age 9 months and older, 30 mg\/kg IV every 6 or 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Lower respiratory tract infection:<\/b> (mild to moderate infections) age 9 months and older, 30 mg\/kg IV every 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Lower respiratory tract infection:<\/b> (moderate to severe infections) age 9 months and older, 30 mg\/kg IV every 6 or 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Peritonitis:<\/b> (mild to moderate infections) age 9 months and older, 30 mg\/kg IV every 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Peritonitis:<\/b> (moderate to severe infections) age 9 months and older, 30 mg\/kg IV every 6 or 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Urinary tract infectious disease:<\/b> (mild to moderate infections) age 9 months and older, 30 mg\/kg IV every 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><li><b>Urinary tract infectious disease:<\/b> (moderate to severe infections) age 9 months and older, 30 mg\/kg IV every 6 or 8 hours (MAX dose, 120 mg\/kg\/day)<\/li><\/ul>"},{"id":"53342-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment (inhalation route):<\/b> no adjustment necessary<\/li><li><b>renal impairment (CrCl 10 to 30 mL\/min\/1.73 m(2)):<\/b> initial, 1 to 2 g; maintenance, 0.5 times the usual initial dose<\/li><li><b>renal impairment (CrCl less than 10 mL\/min\/1.73 m(2)):<\/b> initial, 0.5 to 2 g; maintenance, 0.25 times the usual initial dose at usual intervals; for severe infection, add 0.125 times the usual initial dose after each hemodialysis session<\/li><li><b>hemodialysis:<\/b> initial, 0.5 to 2 g; maintenance, 0.25 times the usual initial dose at usual intervals; for severe infection, add 0.125 times the usual initial dose after each hemodialysis session<\/li><li><b>geriatrics:<\/b> dose based on renal function<\/li><\/ul>"},{"id":"53342-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Cystic fibrosis<\/li><li>Disease due to Gram-negative bacteria<\/li><li>Endometritis<\/li><li>Female genital infection<\/li><li>Infection of skin AND\/OR subcutaneous tissue<\/li><li>Infectious disease of abdomen<\/li><li>Lower respiratory tract infection<\/li><li>Peritonitis<\/li><li>Septicemia<\/li><li>Urinary tract infectious disease<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Bacterial meningitis<\/li><li>Bacterial musculoskeletal infection<\/li><li>Febrile neutropenia, Empiric therapy<\/li><li>Gonorrhea<\/li><li>Postoperative infection; Prophylaxis<\/li><li>Traveler's diarrhea<\/li><\/ul>"}]},"3":{"id":"53342-s-3","title":"Contraindications\/Warnings","sub":[{"id":"53342-s-3-9","title":"Contraindications","mono":"hypersensitivity to aztreonam or any component of the product <br\/>"},{"id":"53342-s-3-10","title":"Precautions","mono":"<ul><li>absence of proven or strongly-suspected infection or use as bacterial prophylaxis; increased risk of developing drug-resistant bacteria<\/li><li>allergic reaction, severe without previous exposure to aztreonam; has been reported<\/li><li>bone marrow transplant patients with concomitant risk factors (i.e., sepsis, radiation therapy, concomitant use of other drugs associated with toxic epidermal necrolysis (TEN)); rare cases of TEN reported<\/li><li>bronchospasm.<\/li><li>clostridium difficile associated diarrhea, including mild diarrhea to fatal colitis; has been reported<\/li><li>concomitant administration with aminoglycoside; risk of nephrotoxicity and\/or ototoxicity, especially with high doses or prolonged therapy<\/li><li>hepatic function, impaired<\/li><li>hypersensitivity to beta-lactam antibiotics (e.g., penicillins, cephalosporins, carbapenems); increased risk of beta-lactam cross-hypersensitivity reaction<\/li><li>pulmonary exacerbation; reduction in forced expiratory volume (FEV) following completion of 28-day regimen (inhalation)<\/li><li>renal failure, severe (creatinine clearance less than 10 mL\/min\/1.73 m(2)); dose reductions required<\/li><li>renal insufficiency, transient or persistent (creatinine clearances between 10 mL\/min\/1.73 m(2) and 30 mL\/min\/1.73 m(2)); dose adjustments required<\/li><li>sensitivity to any allergens, history of; increased risk of hypersensitivity reaction with or without prior exposure.<\/li><li>superinfection; may result in overgrowth of nonsusceptible organisms (e.g., gram-positive\/negative organisms and fungi)<\/li><\/ul>"},{"id":"53342-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"53342-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"5":{"id":"53342-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Chest discomfort (inhalation solution, 8%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (inhalation solution, 7%), Vomiting (inhalation solution, 6%)<\/li><li><b>Hepatic:<\/b>Alkaline phosphatase raised, ALT\/SGPT level raised (pediatrics, 6.5%), AST\/SGOT level raised (pediatrics, 3.8%)<\/li><li><b>Renal:<\/b>Serum creatinine raised (pediatrics, 5.8%)<\/li><li><b>Respiratory:<\/b>Cough (inhalation solution, 54%), Nasal congestion (inhalation solution, 16%), Pain in throat (inhalation solution, 12%), Wheezing (inhalation solution, 16%)<\/li><li><b>Other:<\/b>Fever (up to 1%; inhalation, 13%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme (adults, less than 1%), Toxic epidermal necrolysis (adults, less than 1%)<\/li><li><b>Gastrointestinal:<\/b>Clostridium difficile colitis, Clostridium difficile diarrhea (adults, less than 1%), Gastrointestinal hemorrhage, Clostridium difficile<\/li><li><b>Hematologic:<\/b>Neutropenia (up to 3.2%), Pancytopenia (adults, less than 1%), Thrombocytopenia (adults, less than 1%)<\/li><li><b>Hepatic:<\/b>Hepatitis (adults, less than 1%), Jaundice (adults, less than 1%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis (adults, less than 1%)<\/li><li><b>Otic:<\/b>Ototoxicity<\/li><li><b>Renal:<\/b>Nephrotoxicity<\/li><li><b>Other:<\/b>Angioedema (adults, less than 1%)<\/li><\/ul>"},"6":{"id":"53342-s-6","title":"Drug Name Info","sub":{"0":{"id":"53342-s-6-17","title":"US Trade Names","mono":"<ul><li>Azactam<\/li><li>Cayston<\/li><\/ul>"},"2":{"id":"53342-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Monobactam<\/li><\/ul>"},"3":{"id":"53342-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"53342-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"53342-s-7","title":"Mechanism Of Action","mono":"Bactericidal against Gram-negative aerobic bacteria by binding to penicillin-binding protein-3(PBP-3), which results in inhibition of bacterial cell wall synthesis and often results ultimately in   cell lysis and death ; filamentation also occurs in Enterobacteriaceae and  P. aeruginosa; does not induce beta-lactamase activity, but has a high degree of stability in the presence of bacterial beta-lactamases; does not bind appreciably to any essential PBPs in gram-positive or anaerobic organisms <br\/>"},"8":{"id":"53342-s-8","title":"Pharmacokinetics","sub":[{"id":"53342-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Inhalation: 1 hr<\/li><li>Tmax, Intramuscular: 1 hr<\/li><li>Bioavailability, Inhalation: low<\/li><li>Bioavailability, Oral: less than 1%<\/li><li>Bioavailability, Intramuscular: completely<\/li><li>Bioavailability, Intraperitoneal: 92%<\/li><\/ul>"},{"id":"53342-s-8-24","title":"Distribution","mono":"<ul><li> Vd: 0.11 to 0.21 L\/kg (Adults); 0.2 to 0.29 L\/kg (Infants and children 1 month to 12 yr); 0.26 to 0.3 L\/kg (Neonates less than 1 month); 0.29 to 0.36 L\/kg (Premature neonates)<\/li><li>Protein binding, Serum: 56 % (inhalation)<\/li><\/ul>"},{"id":"53342-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: 7%<\/li><li>Hydrolyzed open beta-lactam ring: inactive<\/li><\/ul>"},{"id":"53342-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 60% to 75%<\/li><li>Fecal: 12%<\/li><li>Dialyzable: Yes (hemodialysis) 27% to 59%; Yes (peritoneal dialysis) 10%<\/li><\/ul>"},{"id":"53342-s-8-27","title":"Elimination Half Life","mono":"1.4 to 2.2 hr (adults); 1.5 to 1.7 hr (children 1 month to 1 yr); 2.4 to 2.6 hr (neonates less than 1 month); 3.1 to 5.7 hr (premature neonates) <br\/>"}]},"9":{"id":"53342-s-9","title":"Administration","mono":"<ul><li><b>Inhalation<\/b><br\/><ul><li>do not administer intravenously or intramuscularly<\/li><li>do not administer or mix with any other nebulized agent<\/li><li>reconstitute with 0.17% sodium chloride diluent supplied<\/li><li>administer short-acting bronchodilators 15 min to 4 hours or long-acting bronchodilators 30 min to 12 hours, then any mucolytics prior to aztreonam for inhalation<\/li><li>use only with the Altera Nebulizer System(R)<\/li><li>administer immediately after reconstitution; do not reconstitute in advance<\/li><\/ul><\/li><li><b>Intramuscular<\/b><br\/><ul><li>reconstitute vial with at least 3 mL of compatible diluent per g; do not mix with local anesthetic agent<\/li><li>inject deep IM into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>(bolus injection) reconstitute vial with 6 to 10 mL Sterile Water for Injection; shake immediately and vigorously<\/li><li>(bolus injection) slowly inject directly into vein or tubing over 3-5 minutes<\/li><li>(infusion) reconstitute vial with at least 3 mL Sterile Water for Injection per g; shake immediately and vigorously; dilute further with compatible solution and shake again<\/li><li>(infusion) infuse over 20-60 minutes<\/li><li>reconstituted solutions are for single dose only; discard unused portion<\/li><\/ul><\/li><\/ul>"},"10":{"id":"53342-s-10","title":"Monitoring","mono":"<ul><li>(infection) CBC<\/li><li>(infection) resolution of signs and symptoms associated with infection, including fever<\/li><li>(cystic fibrosis) improvement in respiratory symptoms (eg, coughing, wheezing, sputum production) and in pulmonary function measured by an increase in FEV1<\/li><li>(injection) renal function and creatinine clearance estimation; especially in patients with diminished renal function including the elderly; serum creatinine may not accurately describe renal status<\/li><li>(injection) hepatic function; in patients with hepatic impairment<\/li><\/ul>"},"11":{"id":"53342-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Injection Powder for Solution: 1 GM, 2 GM<br\/><\/li><li><b>Azactam<\/b><br\/><ul><li>Injection Powder for Solution: 1 GM, 2 GM<\/li><li>Intravenous Solution: 1 GM\/50 ML, 2 GM\/50 ML<\/li><\/ul><\/li><li><b>Cayston<\/b><br\/>Inhalation Powder for Solution: 75 MG\/Vial<br\/><\/li><li><b>Novaplus Aztreonam<\/b><br\/>Injection Powder for Solution: 1 GM, 2 GM<br\/><\/li><li><b>PremierPro Rx aztreonam<\/b><br\/>Injection Powder for Solution: 1 GM, 2 GM<br\/><\/li><\/ul>"},"13":{"id":"53342-s-13","title":"Clinical Teaching","mono":"<ul><li>The injection formulation of this drug may cause nausea, vomiting, or diarrhea. The inhalation formulation may cause cough, nasal congestion, wheezing, sore throat, and fever.<\/li><li>Instruct patient to report signs\/symptoms of bronchospasm (inhalation formulation).<\/li><li>Instruct patient to report signs\/symptoms of thrombophlebitis, pancytopenia, or hepatotoxicity.<\/li><li>Instruct patient to report severe diarrhea and consult healthcare professional prior to taking anti-diarrhea medicine.<\/li><li>Advise patient to use a bronchodilator prior to aztreonam administration (inhalation formulation).<\/li><li>Advise patient to take all 3 daily doses as long as doses are at least 4 hours apart (inhalation formulation).<\/li><\/ul>"}}}